Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

IgA Vasculitis Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

6 recruiting trials for IgA Vasculitis. Eligibility criteria explained in plain English.

TrialFinderData lists 6 IgA Vasculitis clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 50% (2 studies); the largest phase groups are Phase 2: 2, Phase 4: 1, Phase 3: 1.

Research is led by University of Pennsylvania (3), Travere Therapeutics, Inc. (1), Christian Medical College, Vellore, India (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Sparsentan (drug, 3 trials), followed by Colchicine, Dapsone.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
6
Total Trials
6
Recruiting Now
1
Phase 3 Trials
4
Sponsors

Track IgA Vasculitis trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 2NCT02939573

A Randomized Multicenter Study for Isolated Skin Vasculitis

Multi-center sequential multiple assignment randomized trial comparing the effectiveness of three different standard of care treatment options for patients with isolated skin...

Sponsor: University of PennsylvaniaEnrolling: 9016 locations
RECRUITINGPhase 2NCT05003986

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.

Sponsor: Travere Therapeutics, Inc.Enrolling: 6720 locations
RECRUITINGPhase 4NCT06676384

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope...

Global Burden of Diseases ranks chronic kidney disease (CKD) as the 12th leading cause of death, with an estimated 20% increase from 2010 to 2019. India is the most populous...

Sponsor: Christian Medical College, Vellore, IndiaEnrolling: 58512 locations
RECRUITINGPhase 3NCT07024563

Study of Ravulizumab in Pediatric Participants With Primary IgAN

The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV...

Sponsor: Alexion Pharmaceuticals, Inc.Enrolling: 2414 locations
RECRUITINGNCT02967068

VCRC Tissue Repository

The purpose of this study is to collect existing tissue specimens from subjects enrolled in Vasculitis Clinical Research Consortium (VCRC) studies. Analysis of these tissue...

Sponsor: University of PennsylvaniaEnrolling: 10008 locations
RECRUITINGNCT02593565

Vasculitis Pregnancy Registry

The purpose of this study is to learn about the experience of women with vasculitis who become pregnant. In particular, the study will consist of several online surveys to assess...

Sponsor: University of PennsylvaniaEnrolling: 1001 location

Frequently Asked Questions

There are currently 6 clinical trials for IgA Vasculitis, with 6 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for IgA Vasculitis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for IgA Vasculitis, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.